Aquestive Therapeutics share price logo

Aquestive Therapeutics

NASDAQ: AQST

Small Cap

$4.78

+0.02

(+0.42%)

as on

Aquestive Therapeutics Stock Performance

as on October 10, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $4.75
    $4.97
    downward going graph

    0.63%

    Downside

    3.97%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.93
    $7.55
    downward going graph

    38.70%

    Downside

    57.95%

    Upside

    downward going graph

Aquestive Therapeutics share price movements today

Previous Close
$4.76
Open
$4.80
Volume
2.1M
Market Cap
$597.4M
Day's Low - High
$4.75 - $4.97
52 Week Low - High
$2.93 - $7.55

Aquestive Therapeutics Historical Returns

1 Month Return
-4.21 %
3 Month Return
+ 16.02 %
1 Year Return
-26.91 %
3 Year Return
+ 241.43 %
5 Year Return
+ 29.54 %

Aquestive Therapeutics Stock Fundamentals & Key Indicators

Check Aquestive Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$597.4M

EPS (TTM)

-0.65

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.32

Industry PE ratio

3.89

PEG Ratio

-6.53

EBITDA

-61.4M

Revenue (TTM)

54.1M

Profit Margin

67.04%

Return On Equity TTM

243.68%

Aquestive Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aquestive Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Aquestive Therapeutics image
Aquestive Therapeutics
Buy$597.4M29.54%-7.3267.04%0.00%
Sandoz Group Ltd Sponsored ADR image
Sandoz Group Ltd Sponsored ADR
Buy$37.5BNA55.9647.54%1.23%
United Therapeutics image
United Therapeutics
Buy$22.9B181.07%17.6286.14%0.00%
Viatris image
Viatris
Buy$20.1B29.42%-48.4434.83%2.75%
Haleon PLC Sponsored ADR image
Haleon PLC Sponsored ADR
Buy$39.9BNA18.9865.57%2.14%
See all

Stock Returns calculator for Aquestive Therapeutics Stock including INR - Dollar returns

The Aquestive Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Aquestive Therapeutics investment value today

Current value as on today

₹79,778

Returns

-₹20,222

(-20.22%)

Returns from Aquestive Therapeutics Stock

-₹26,911 (-26.91%)

Dollar Impact

₹6,689 (+6.69%)

Analyst Recommendation on Aquestive Therapeutics Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Aquestive Therapeutics. Average target price of $9.33

Aquestive Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Aquestive Therapeutics.

What analysts predicted

48.77%UPSIDE

Target Price

$9.33

Current Price

$4.78

Analyzed by

2 Analysts

High

$10

Target

$9.33

Low

$6

Aquestive Therapeutics target price $9.33, a slight upside of 48.77% compared to current price of $4.78. According to 2 analysts rating.

Indian Investors' Interest in Aquestive Therapeutics Stock

Search interest for Aquestive Therapeutics Stock has decreased by -49% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-49% versus previous 30 day period

Aquestive Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
12
20
13
11
8
10
12
13
14
13
Gross Profit
7
15
9
7
5
5
8
7
10
9
Operating Income
-8
0
-8
-13
-19
-11
-11
-28
-4
-8
EBITDA
-8
1
-7
-12
-18
-9
-11
-27
-4
-18
Interest Expense
4
4
4
4
4
4
4
4
3
3
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-12
-2
-11
-17
-22
-13
-15
-31
-8
-22
Income Tax Expense
-
-
-
0
-
-
-
-
-
-
Net Income
-12
-2
-11
-17
-22
-13
-15
-31
-8
-22
Net Profit Margin
63.59%
77.48%
67.24%
61.91%
58.12%
54.40%
64.82%
55.16%
75.99%
70.93%

Aquestive Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
66
67
52
45
50
47
50
57
44
Gross Profit
47
46
32
32
35
28
29
39
27
Operating Income
0
-48
-52
-42
-34
-42
-15
-30
-69
EBITDA
2
-50
-54
-39
-45
-39
1
-26
-66
Interest Expense
7
7
9
13
22
12
7
16
17
Depreciation
3
3
2
3
2
2
1
0
0
Income Before Tax
-8
-61
-66
-55
-70
-54
-7
-44
-83
Income Tax Expense
-
-
-
-
-
-
0
0
-
Net Income
-8
-61
-66
-55
-70
-54
-7
-44
-83
Net Profit Margin
70.38%
68.87%
61.30%
71.72%
70.51%
59.34%
58.82%
68.95%
61.49%

Aquestive Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-12
-2
-11
-17
-22
-13
-15
-31
-8
-22
Operating Cash Flow
-10
-7
-11
-6
-23
-7
-12
-8
-14
-9
Investing Cash Flow
0
0
0
0
0
0
0
0
0
0
Financing Cash Flow
81
1
0
0
20
0
81
0
4
-2
Change in Cash
71
-5
-11
-6
-2
-8
68
-7
-10
-12

Aquestive Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-8
-61
-66
-55
-70
-54
-7
-44
-83
Operating Cash Flow
5
-12
-60
-45
-32
-9
-6
-35
-52
Investing Cash Flow
-2
-1
0
0
0
-2
0
0
0
Financing Cash Flow
4
58
49
28
30
11
3
83
102
Change in Cash
8
43
-11
-17
-3
0
-3
47
49

Global Institutional Holdings in Aquestive Therapeutics

Check out the Institutions with significant holdings in Aquestive Therapeutics.

Funds
Holdings
Vanguard
4.17%
iShares
3.68%
VANGUARD INDEX FUNDS
3.45%
Federated Hermes MDT Series
1.50%
SPDR
1.28%
See all

Aquestive Therapeutics News & Key Events

  • img

    Today's Timeline - 08 October

    Wed, 05:20 PM

    -

    Aquestive Therapeutics secures two new U.S. patents for Anaphylm, extending protection until 2037, potentially transforming anaphylaxis treatment.

Insights on Aquestive Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, AQST has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, AQST stock has moved up by 250.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Viatris Inc. Common Stock has given 81.1% return, outperforming this stock by 108.0%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 14.44M → 13.81M (in $), with an average decrease of 4.3% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -8.05M → -22.86M (in $), with an average decrease of 183.8% per quarter

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
OrganisationAquestive Therapeutics
Headquarters30 Technology Drive, Warren, NJ, 07059, US
IndustryDrug Manufacturers - Specialty & Generic
CEODaniel Barber

Key Management of Aquestive Therapeutics

Name

Title

Mr. Daniel Barber

CEO, President & Director

Mr. Peter E. Boyd

Senior Vice President of Information Technology & Chief People Officer

Ms. Sherry Korczynski

Chief Commercial Officer

Dr. Melina T. Cioffi Pharm.D.

Senior Vice President of Regulatory Affairs

Dr. Matthew William Davis M.D., R.Ph.

Chief Development Officer

Mr. A. Ernest Toth Jr.

Senior VP & CFO

Ms. Lori J. Braender BSBA, Esq., J.D.

Corporate Secretary

Ms. Cassie Jung

Chief Operating Officer

Mr. Thomas A. Zalewski

Chief Legal Officer & Chief Compliance Officer

Dr. Matthew Greenhawt B.Sc., M.B.A., M.D.

Chief Medical Officer

FAQs

What is Aquestive Therapeutics share price today?

Aquestive Therapeutics share price today is $4.78 as on at the close of the market. Aquestive Therapeutics share today touched a day high of $4.97 and a low of $4.75.

What is the 52 week high and 52 week low for Aquestive Therapeutics share?

Aquestive Therapeutics share touched a 52 week high of $7.55 on and a 52 week low of $2.93 on . Aquestive Therapeutics stock price today i.e. is closed at $4.78,which is 36.69% down from its 52 week high and 63.14% up from its 52 week low.

What is Aquestive Therapeutics's market capitalisation today?

Aquestive Therapeutics market capitalisation is $0.00T as on .

How to invest in Aquestive Therapeutics Stock (AQST) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Aquestive Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Aquestive Therapeutics Stock (AQST) from India?

Indian investors can start investing in Aquestive Therapeutics (AQST) shares with as little as ₹96.779998779297 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹967.80 in Aquestive Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Aquestive Therapeutics share’s latest price of $4.78 as on October 10, 2026 at 8:46 am IST, you will get 2.0921 shares of Aquestive Therapeutics. Learn more about fractional shares .

What are the returns that Aquestive Therapeutics has given to Indian investors in the last 5 years?

Aquestive Therapeutics stock has given 29.54% share price returns and 28.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?